Vision impairment, particularly contrast sensitivity deficits, may account for up to 19% of dementia cases in older US adults, suggesting a potential target for prevention strategies.
“Overall, TS was found to double the screening compliance rates in certain populations, particularly in underserved areas where access to ophthalmic care is limited.”
Biomea Fusion announced a clinical hold by the U.S. FDA on its diabetes drug trial due to potential toxic liver disease, causing a 60% drop in its shares.